Apologies, sorry to hear that. There has been a fair bit of bickering and banter on here about how if a test doesn't go our way it slowly disappears without an explanation and a new focus takes its place. A few longer term holders like myself are increasingly negative towards RCE.
Regarding Sepsis. It would appear to the layman that the plasma concentrations in human testing were far too low to be effective, when compared with the aminal trials. RCE denied this yet did an additional phase 1 where they increased the dosages. However, the second time around they did not release the plasma concentration data. In an interview a board member said the concentrations were adequate, yet after this, Sepsis ceased to be the companies focus. Over the space of the next few months it became a side note as UTI and then topical became the goal. Whilst we don't have the data, a pretty obvious inference can be made.
There is more to the story and other percieved shortcomings of the board over the last few years but in a nutshell, many long term holders have become increasingly concerned about management's transparency and competency.
All the best with the health.
(20min delay)